Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ADR-529

Known as: ADR 529, ADR529 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DexrazoxaneDexrazoxane hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529
SummaryThe purpose of this study was to evaluate the optimal timing of ADR-529 administration to protect rats treated with… Expand
  • figure 1
  • table 1
Highly Cited
1996
Highly Cited
1996
Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Dexrazoxane [(DZR), ADR 529, ICRF-187] ameliorates doxorubicin (DOX)-induced cardiotoxicity in animals, and is recommended as a… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Review
1995
Review
1995
Cardiotoxicity and cardioprotection during chemotherapy.
Chemotherapy drugs have been reported to cause cardiac side effects including cardiomyopathy, ischemia, arrhythmias, and… Expand
Highly Cited
1994
Highly Cited
1994
Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and…
Certain bis(2,6-dioxopiperazine) derivatives, which include ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl]propane; ADR-529) and… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 5
Highly Cited
1993
Highly Cited
1993
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and…
The effect of the bisdioxopiperazine cardioprotector ICRF-187 (ADR-529, dexrazoxan) on drug-induced DNA damage and cytotoxicity… Expand
Highly Cited
1992
Highly Cited
1992
Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
In this study doxorubicin, epirubicin, and mitoxantrone were compared for their cardiotoxic potential in a chronic mouse model in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1992
Highly Cited
1992
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.
BACKGROUND Although doxorubicin is an anticancer agent with a wide spectrum of activity, therapy with this anthracycline must… Expand
1992
1992
In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex.
ADR-529 protects against anthracycline cardiotoxicity, possibly by preventing free radical induction. We hypothesize that this… Expand
Review
1991
Review
1991
ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.
Anthracyclines are anticancer agents that are effective in a wide range of tumors. Unfortunately, their activity is limited by… Expand
1990
1990
dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase…
Iron-catalyzed free radical reactions, such as the peroxidation of membrane lipids or the inactivation of critical enzymes, have… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE